Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hepatocellular carcinoma

Have we finally found the ultimate staging system for HCC?

Nature Reviews Gastroenterology & Hepatology volume 11, pages 334–336 (2014)Cite this article

Subjects

This article has been updated

A staging system capable of addressing the real issues facing patients with hepatocellular carcinoma has long been overdue. The new Hong Kong Liver Cancer staging system might do just that because it deals effectively with the limitations of previous staging systems.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 08 May 2013

    In the version of this article originally published online, the Node criterion for the BCLC staging system was incorrect in Table 1. The error has been corrected for the HTML and PDF versions of the article.

References

  1. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012).

    Article  PubMed  Google Scholar 

  2. European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).

  3. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  PubMed  Google Scholar 

  4. Burrel, M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J. Hepatol. 56, 1330–1335 (2012).

    Article  PubMed  Google Scholar 

  5. Llovet, J. M., Schwartz, M., Fuster, J. & Bruix, J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin. Liver Dis. 26, 248–253 (2006).

    Article  PubMed  Google Scholar 

  6. Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329–338 (1999).

    Article  CAS  PubMed  Google Scholar 

  7. Yau, T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology, http://dx.doi.org/10.1053/j.gastro.2014.02.032 (2014).

  8. Lencioni, R. et al. GIDEON (Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int. J. Clin. Pract. http://dx.doi.org/10.1111/ijcp.12352 (2013).

Download references

Author information

Authors and Affiliations

  1. Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Sheikh Zayed Tower, Suite 7203, 1800 Orleans Street, Baltimore, 21287, MD, USA

    Julius Chapiro & Jean-François Geschwind

Authors
  1. Julius Chapiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-François Geschwind
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-François Geschwind.

Ethics declarations

Competing interests

J.-F.G. acts as a consultant for the following companies: Bayer HealthCare, Biocompatibles/BTG, Guerbet, Jennerex, Nordion/BTG and Philips Healthcare. J.-F.G. is also the founder and CEO of PreScience Labs, LLC. J.C. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chapiro, J., Geschwind, JF. Have we finally found the ultimate staging system for HCC?. Nat Rev Gastroenterol Hepatol 11, 334–336 (2014). https://doi.org/10.1038/nrgastro.2014.67

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.67

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing